既往心力衰竭与老年弥漫大B细胞淋巴瘤患者结局的关联
分析显示既往心衰者接受蒽环类治疗的可能性更低(OR 0.55,95%CI 0.49-0.61),且淋巴瘤死亡率更高( adjusted HR 1.24,95%CI 1.18-1.31),提示该高危人群需专门试验。
要点
- 老年DLBCL患者中既往心衰患病率为13.9%。
- 既往心衰者接受蒽环类治疗的OR为0.55(95%CI 0.49-0.61)。
- 既往心衰与淋巴瘤死亡率升高相关(HR 1.24,95%CI 1.18-1.31)。
核心结论
- 在新诊断DLBCL的老年患者中,既往心衰常见,且与蒽环类及任何化疗使用减少相关,并与淋巴瘤死亡率升高相关。
主要发现
- 既往心衰者接受蒽环类治疗的比值比为0.55(95%CI 0.49-0.61)。
- 在既往心衰且接受蒽环类的患者中,右雷佐生或脂质体多柔比星的使用比例为78/1119(7.0%)。
- 既往心衰者的1年淋巴瘤死亡率为41.8%(95%CI 40.5-43.2),无既往心衰者为29.6%(95%CI 29.0-30.1)。
- 调整基线和时变治疗因素后,既往心衰与淋巴瘤死亡率升高相关(风险比1.24,95%CI 1.18-1.31)。
临床怎么用
- 对老年DLBCL患者应评估既往心衰,以识别蒽环类使用可能受限且淋巴瘤死亡风险较高的人群。
- 既往心衰患者接受蒽环类时,可考虑心脏保护策略如右雷佐生或脂质体多柔比星,但原文中实际使用比例较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality. OBJECTIVE: To assess the prevalence of preexisting HF in older patients with DLBCL and its association with treatment patterns and outcomes. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare registry from 1999 to 2016. The SEER registry is a system of population-based cancer registries, capturing more than 25% of the US population. Linkage to Medicare offers additional information from billing claims. This study included individuals 65 years and older with newly diagnosed DLBCL from 2000 to 2015 with Medicare Part A or B continuously in the year prior to lymphoma diagnosis. Data were analyzed from September 2020 to December 2022. EXPOSURES: Preexisting HF in the year prior to DLBCL diagnosis ascertained from billing codes required one of the following: (1) 1 primary inpatient discharge diagnosis, (2) 2 outpatient diagnoses, (3) 3 secondary inpatient discharge diagnoses, (4) 3 emergency department diagnoses, or (5) 2 secondary inpatient discharge diagnoses plus 1 outpatient diagnosis. MAIN OUTCOMES AND MEASURES: The primary outcome was anthracycline-based treatment. The secondary outcomes were (1) cardioprotective medications and (2) cause-specific mortality. The associations between preexisting HF and cancer treatment were estimated using multivariable logistic regression. The associations between preexisting HF and cause-specific mortality were evaluated using cause-specific Cox proportional hazards models with adjustment for comorbidities and cancer treatment. RESULTS: Of 30 728 included patients with DLBCL, 15 474 (50.4%) were female, and the mean (SD) age was 77.8 (7.2) years. Preexisting HF at lymphoma diagnosis was present in 4266 patients (13.9%). Patients with preexisting HF were less likely to be treated with an anthracycline (odds ratio, 0.55; 95% CI, 0.49-0.61). Among patients with preexisting HF who received an anthracycline, dexrazoxane or liposomal doxorubicin were used in 78 of 1119 patients (7.0%). One-year lymphoma mortality was 41.8% (95% CI, 40.5-43.2) with preexisting HF and 29.6% (95% CI, 29.0%-30.1%) without preexisting HF. Preexisting HF was associated with higher lymphoma mortality in models adjusting for baseline and time-varying treatment factors (hazard ratio, 1.24; 95% CI, 1.18-1.31). CONCLUSIONS AND RELEVANCE: In this study, preexisting HF in patients with newly diagnosed DLBCL was common and was associated with lower use of anthracyclines and lower use of any chemotherapy. Trials are needed for this high-risk population.
引用
- Upshaw, Nelson, Rodday, et al. Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. JAMA Cardiol. 2023. PMID: 36988926. doi:10.1001/jamacardio.2023.0303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。